Literature DB >> 31582369

Pembrolizumab: living up to expectations.

Stephen M Ansell1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 31582369     DOI： 10.1182/blood.2019002417

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  4 in total

1.  Pingyangmycin enhances the antitumor efficacy of anti-PD-1 therapy associated with tumor-infiltrating CD8+ T cell augmentation.

Authors:  Chuan-Kun Shan; Yi-Bo Du; Xiao-Tian Zhai; Yue-Xuan Wang; Yi Li; Jian-Hua Gong; Zhi-Juan Ge; Xiu-Jun Liu; Yong-Su Zhen
Journal:  Cancer Chemother Pharmacol       Date:  2021-01-03       Impact factor: 3.333

Review 2.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-14       Impact factor: 8.110

Review 3.  Trial Watch: experimental TLR7/TLR8 agonists for oncological indications.

Authors:  Giorgio Frega; Qi Wu; Julie Le Naour; Erika Vacchelli; Lorenzo Galluzzi; Guido Kroemer; Oliver Kepp
Journal:  Oncoimmunology       Date:  2020-07-21       Impact factor: 8.110

Review 4.  Trial watch: TLR3 agonists in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-02       Impact factor: 8.110
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.